Andy Hurley Named Agenus Chief Commercial Officer
10 February 2021 - 9:06AM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of checkpoint antibodies, cell therapies,
adjuvants, and vaccines designed to activate immune response to
cancers and infections, today announced the appointment of Andy
Hurley as its Chief Commercial Officer.
“We welcome Andy Hurley as we transition into a commercial stage
company with a robust research and clinical pipeline,” said Garo
Armen, PhD, Chairman and CEO of Agenus. “Andy’s experience and
passion in successfully commercializing biopharmaceutical agents
and his excitement about our portfolio made him a natural fit to
join our team.”
"I am excited to join Agenus, one of the true pioneers in
immuno-oncology, to lead the efforts for its first potential
commercial product launch and to help determine the optimal
commercial path for Agenus’ vast and differentiated pipeline,” said
Andy Hurley, Chief Commercial Officer at Agenus. “I am excited
about the potential of balstilimab alone and in combination with
Agenus’ other novel candidates, like AGEN1181, to bring potentially
life-altering therapies to patients.”
Andy brings to Agenus three decades of international experience
as a strategic commercial leader at large and small
biopharmaceutical companies. He joins Agenus from his most recent
role as the Senior Vice President at Syneos Health. Before Syneos
Health, he was Chief Commercial Officer at Ocular Therapeutix where
he was hired to pivot the organization from an R&D company to a
fully integrated commercial company. Andy also held executive
leadership roles at Sunovion, Dyax, and Forest Pharmaceuticals. He
holds a Bachelor of Science in Consumer Studies from the University
of Vermont.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its AgenTus Therapeutics subsidiary), and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter
handle @agenus_bio. Information that may be important to investors
will be routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding commercialization and the anticipated
commercial launch of Agenus’ candidates, as well as their
therapeutic potential. These forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
Contact:Agenus
Inc. Caroline
Bafundo 212-994-8209Caroline.Bafundo@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2023 to May 2024